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Abstract
Background: Hepcidin acts as the main regulator of iron homeostasis through regulation of intestinal absorption
and macrophage release. Hepcidin deficiency causes iron overload whereas its overproduction is associated with
anaemia of chronic diseases. The aims of the study were: to identify genetic variants in the hepcidin gene (HAMP)
promoter, to asses the associations between the variants found and iron status parameters, and to functionally
study the role on HAMP expression of the most frequent variant.
Results: The sequencing of HAMP promoter from 103 healthy individuals revealed two genetic variants: The c.-
153C > T with a frequency of 0.014 for allele T, which is known to reduce hepcidin expression and the c.-582A > G
with a 0.218 frequency for allele G. In an additional group of 224 individuals, the c.-582A > G variant genotype
showed no association with serum iron, transferrin or ferritin levels.
The c.-582G HAMP promoter variant decreased the transcriptional activity by 20% compared to c.-582A variant in
cells from the human hepatoma cell line HepG2 when cotransfected with luciferase reporter constructs and plas-
mid expressing upstream stimulatory factor 1 (USF1) and by 12-14% when cotransfected with plasmid expressing
upstream stimulatory factor 2 (USF2).
Conclusions: The c.-582A > G HAMP promoter variant is not associated with serum iron, transferrin or ferritin levels
in the healthy population. The in vitro effect of the c.-582A > G variant resulted in a small reduction of the gene
transactivation by allele G compared to allele A. Therefore the effect of the variant on the hepcidin levels in vivo
would be likely negligible. Finally, the c.-153C > T variant showed a frequency high enough to be considered
when a genetic analysis is done in iron overload patients.
Background
Hepcidin was first isolated from urine as an antimicro-
bial peptide [1] and thereafter, it has been shown to act
as the main regulator of iron homeostasis through regu-
lation of intestinal iron absorption and macrophage iron
release [2-5]. The first evidence was provided by mice
studies which showed increased hepcidin mRNA levels
in the liver of iron overload mice [6]. Further animal
models and human disorders confirmed the relationship
between this peptide and iron. Genetically modified
mice showed that animals with reduced hepcidin
expression developed severe iron overload [7], while
those with increased expression had severe iron defi-
ciency anaemia at birth [8]. In humans, inactivating
mutations of hepcidin result in a rare form of juvenile
haemochromatosis [9], whereas hepcidin overexpression
in inflammation causes anaemia of chronic diseases with
features of iron restricted erythropoiesis [10]. Besides,
hepcidin has been described as a modifier peptide that
exacerbates the phenotypic expression of patients with
hereditary haemochromatosis (HFE) homozygous for the
common HFE gene mutation, p.Cys282Tyr [11-13].
The gene encoding hepcidin, HAMP, is mainly
expressed in the liver in situations of iron overload [14].
It is upregulated by hemojuvelin [15], transferrin recep-
tor 2 [16] and HFE protein [17] mediated through the
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bone morphogenetic protein (BMP) signalling pathway
[18]. Hepcidin is also upregulated in inflammation by
interleukin 6 (IL-6) and other cytokines through the
Janus kinase/signal transducer and activator of tran-
scription (JAK/STAT) signalling pathway [6,10,19]. Hep-
cidin is inhibited by hypoxia [20] and augmented
erythropoiesis [21]. More recently, matriptase-2 has
been described as the first known negative regulator of
hepcidin expression [22].
Lately, two genetic variants in the HAMP promoter have
been described as modulators of iron overload. Firstly, the
c.-582A > G variant has been associated with higher liver
iron concentration and with higher serum ferritin levels in
beta-thalassemic patients [23]. Secondly, the c.-153C > T
mutation, which is located within a BMP-Responsive Ele-
ment, has been shown to contribute to a severe phenotype
in HFE related haemochromatosis [11].
The aim of the study was to identify genetic variants
in the HAMP promoter and their frequency distribution
in the Galician population. Another objective was to
assess possible associations between these variants and
the serum iron, serum transferrin and serum ferritin
levels in a random sample of Galician probands. Finally,
we performed functional in vitro studies to determine
the effect of variants on HAMP expression.
Results
Identification of genetic variants in the hepcidin gene
promoter
The sequencing of the HAMP promoter in the random
sample of 103 healthy individuals allowed the identifica-
tion of two genetic variants each with an allele fre-
quency higher than 0.01. Therefore, both loci could be
considered polymorphic. The first variant c.-582A > G
was found in 49 promoter sequences (58 individuals
were homozygous for allele A, 41 heterozygous AG and
4 homozygous GG), which resulted in an allele fre-
quency of 0.762 for c.-582A and 0.218 for c.-582G. This
variant corresponded to single nucleotide polymorphism
(SNP) rs10421768 in the NCBI SNP database http://
www.ncbi.nlm.nih.gov/snp/. The second variant c.-153C
> T was found in only three heterozygous CT. Thus
allele frequency of allele c.-153T was 1.4%. Furthermore,
unique variants were found in two heterozygous indivi-
duals: c.-572C > T and c.-188C > T. No transcription
factor binding sites were predicted for these unique var-
iants http://www.biobase-international.com/pages/index.
php?id=transfac.
G genotype and its relation with biochemical
parameters",1,0,1,0,0pc,0pc,0pc,0pc>c.-582A > G
genotype and its relation with biochemical parameters
The genotype frequencies of the SNP located 582 bp
upstream did not differ significantly between our sample
of 224 individuals and the 103 healthy probands initially
studied. No significant differences were found in the
levels of serum iron, serum transferrin, transferrin
saturation or ferritin levels between the c.-582A > G
variant genotypes (Table 1). No significant differences
were found either when males and females were strati-
fied (data not shown).
Transactivation assays
The fold activation of VarA-Hep/Luc construct was 3.19
± 0.10 in basal conditions and it increased to 7.99 ±
0.24 when cells were cotransfected with pCMV-USF1,
13.88 ± 0.53 with pCMV-USF2 and 9.92 ± 0.26 with
pCMV-USF1+ pCMV-USF2. These results indicated
that either USF1, USF2 or the combination of both
(USF1+USF2 (1:1)) can transactivate VarA-Hep/Luc
construct with a 2.5 ± 0.3, 4.3 ± 0.7 and 3.1 ± 0.3 (mean
± SEM) fold induction, respectively (Figure 1). The same
experiments carried out for the VarG-Hep/Luc con-
struct gave similar results. The fold activation of the
VarG-Hep/Luc construct in basal conditions was 2.84 ±
0.33 and it increased to 6.36 ± 0.19 when cotransfected
with pCMV-USF1, 12.27 ± 0.38 with pCMV-USF2 and
8.34 ± 0.23 with pCMV-USF1+ pCMV-USF2 (1:1 ratio).
These meant a 2.2 ± 0.3, 4.3 ± 0.5 and 3.0 ± 0.4 (mean
± SEM) fold induction driven by USF1, USF2 or USF1
+USF2 (1:1), respectively (Figure 2).
The c.-582G variant slightly decreased HAMP promo-
ter transcriptional activity. Basal luciferase activity from
VarG-Hep/Luc construct was 88.8% compared to that of
VarA-Hep/Luc construct. When those constructs were
transactivated with USF1, the VarG-Hep/Luc showed a
significant 20% decrease in activity compared to VarA-
Hep/Luc (p < 0.001). When transactivated with USF2
and USF1+USF2 a 12-14% reduction was obtained for
the VarG-Hep/Luc with respect to VarA-Hep/Luc (p >
0.05 and p < 0.05, respectively) (Figure 3).
Table 1 Serum iron, serum transferrin, serum ferritin and
transferrin saturation according to HAMP c.-582A > G
genotype in Galician population
c.-582A > G Genotype
A/A A/G and G/G
N (%) 128 (57.1) 96 (42.9)
SI mean ± SD (μg/dL) 55.6 ± 30.7 55.5 ± 31.2
ST mean ± SD (mg/dL) 265.7 ± 28.0 263.6 ± 30.8
SF mean ± SD (μg/dL) 95.9 ± 73.7 106.6 ± 74.5
TS mean ± SD (%) 15.0 ± 8.5 15.2 ± 8.8
SI: Serum iron, ST: serum transferrin, SF: serum ferritin, TS transferrin
saturation
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Discussion
Hepcidin is the main regulator of iron homeostasis and,
therefore, a better understanding of its regulation is of
great interest. In the present work, we sequenced, in an
initial sample group, the promoter of the hepcidin gene,
HAMP. This allowed the identification of two genetic
polymorphic variants in our population. In a further
group of individuals the c.-582A > G was genotyped and
a possible relationship with biochemical iron status mar-
kers was studied. In addition, we performed functional-
in-vitro analysis to characterize the effect of the c.-582A
> G variant on the hepcidin gene transactivation.
In the present work, we first sequenced the promoter
of the hepcidin gene HAMP in a group of 103 healthy
individuals. This allowed the identification of two poly-
morphic sites. In another group of 224 individuals, the
c.-582A > G variant was genotyped and its possible rela-
tionship with biochemical data as well as its effect on
HAMP transactivation was studied. The frequency dis-
tribution of this SNP in the Galician population is simi-
lar to that of a cohort of Italian healthy donors [24] and
furthermore to those of other European populations
http://www.ncbi.nlm.nih.gov/snp/.
The c.-582A > G variant is located within an E-box,
which is a responsive element for helix-loop-helix tran-
scription factors (bHLH-ZIP). The canonical sequence of
the E-box is CACGTG (consensus CANNTG). When the
A is substituted by G, the E-box would be abolished and
unable to bind the transcription factors. USF1 and USF2
are bHLH-ZIP transcription factors that have been shown
to positively regulate hepcidin expression through E-boxes
within the promoter [25]. Therefore, we decided to study
the in-vitro effect of the c.-582A > G variant on the
HAMP transactivation in response to USF stimulation.
Our results confirmed the ability of USF1 and USF2 to
transactivate the HAMP promoter in HepG2 cells. Addi-
tionally, we found that the USF transactivation was main-
tained in the c.-582G promoter. However, the USF
promoter transactivation was slightly reduced in the case
of the c.-582G allele compared to c.-582A. The subtle
decrease in transactivation might be caused by the fact
that only one of the four E-boxes present in the promoter
is affected. Nonetheless, it can not be ruled out that differ-
ent endotoxin content or slightly incorrect DNA estima-
tion in the plasmid preparations caused the small
differences found between the two variants.
No significant association between the c.-582A > G
genotype and serum iron, serum transferrin, transferrin
saturation or ferritin levels were found, which might
reflect no differences in liver iron concentration. These
results are in agreement with Bruno and col. that did
not find association either [24]. Conversely, this associa-
tion was found among a series of thalassemia major
patients. The experiments performed in the HepG2 cells
Figure 1 Functional analysis of the c.-582A variant .
Cotransfection of HepG2 cells with pCMV-USF1, pCMV-USF2 or
pCMV-USF1+ pCMV-USF2 (1:1) increased the promoter activation
compared to cells transfected with VarA-Hep/Luc constructs alone
(basal). Data represent means of three independent experiments (±
SEM) ***p < 0.001
Figure 2 Functional analysis of the c.-582A variant .
Cotransfection of HepG2 cells with pCMV-USF1, pCMV-USF2 or
pCMV-USF1+ pCMV-USF2 (1:1) increased the promoter activation
compared to cells transfected with VarG-Hep/Luc constructs alone
(basal). Data represent means of three independent experiments (±
SEM) ***p < 0.001
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showed, at its maximum, a 20% transactivation reduc-
tion by the c.-582G allele, compared to c.-582A. In addi-
tion, one has to bear in mind that the in-vitro model
used may not completely reflect what happens in-vivo.
This data together with the fact that HAMP is regulated
by many different signals [6,10,15-18,20-22] suggested
that the effect of the c.-582A > G polymorphism on
hepcidin levels, and therefore on the iron status in-vivo
is most likely negligible. We hypothesize that the c-
.582A > G variant in the human HAMP promoter
would have no effect on the hepcidin transcription in
normal situations but it might have some effect in phy-
siopathological situations where more hepcidin was
needed. However, further studies would be necessary to
confirm this hypothesis.
The variation at the second polymorphic site, c.-153C >
T, in the promoter region of the hepcidin gene had been
previously identified in a patient with massive iron over-
load homozygous for the p.Cys282Tyr mutation in HFE
[11]. Island and col. demonstrated that the c.-153C > T
mutation, which is located in a BMP-Responsive Element,
reduced basal hepcidin gene expression and impaired its
response to BMPs and IL-6. This variation has been found
at a very low frequency by other investigators: Island and
col. did not found it in 200 chromosomes from healthy
volunteers [11], Barton and col. found a frequency of
0.06% among 785 Haemochromatosis and Iron Overload
Screening (HEIRS) Study participants [26]. Both groups
concluded that the variation in haemochromatosis patients
is not worth to study. On the other hand, Aguilar-Marti-
nez and col. found the variant with a 5% frequency in a
group of haemochromatosis patients without the p.
Cys282Tyr mutation in HFE, whilst in healthy individuals
of the same population the allele frequency was only 0.4%.
They suggested that this variant should be studied in a
selected iron overload patients [27]. Our finding of a 1.4%
frequency of the c.-153T allele in the Galician population
additionally supports this recommendation for genotyping
this locus in iron overload Galician patients.
Conclusions
Due to the role of hepcidin as a key modulator of sys-
temic iron levels, it is plausible that differences in the
level of its expression may partly account for the pheno-
typic variant in iron metabolism between individuals. In
this report, no association was found between serum
iron, transferrin or ferritin levels and the c.-582A > G
HAMP promoter variant in a healthy population. This
result was supported by the functional in-vitro studies,
which showed only a 10-20% reduction of the promoter
transactivation by allele c.-582G compared to the c.-
582A allele.
Figure 3 The c.-582A > G variant decreases hepcidin promoter transcription activity. HepG2 cells were transfected with VarA-Hep/Luc or
VarG-Hep/Luc constructs alone (basal) and cotransfected with pCMV-USF1, pCMV-USF2 or pCMV-USF1+ pCMV-USF2 (1:1). Data represent means
of three independent experiments (± SEM) ***p < 0.001, *p < 0.05
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Methods
Sample population
A total of 327 individuals were used for the present
study. Initially, a sample of 103 healthy individuals was
recruited from the university students and employees of
the Hospital Clínico Universitario at Santiago de Com-
postela. Information about their parents’ and grandpar-
ents’ geographic origins was provided and all were from
the Spanish Galician region, which is a relatively iso-
lated European population at the westernmost continen-
tal edge. A second independent random sample of 224
individuals was randomly recruited from the general
adult population of the Galician town La Estrada.
Serum ferritin levels of this group were between 10-300
ng/mL. Detailed description has been reported else-
where [28]. Informed consent was obtained from each
participant. All the procedures were conducted accord-
ing to the principles expressed in the Declaration of
Helsinki and to the ethical standards of the local Ethics
Committee.
Biochemical determinations
Serum iron and serum transferrin were assayed in an
ADVIA-2400 Chemistry System (Siemens Medical Diag-
nostics, Germany) and serum ferritin was measured in an
ADVIA-Centaur Immunoassay System (Siemens). Trans-
ferrin saturation (TS) was calculated with the following
formula: TS (in %) = [serum iron (in μg/dL) × 71]/serum
transferrin (in mg/dL). With these methods, normal con-
centrations in adults are as follows: serum iron, 45-160
μg/dL (males) and 40-150 μg/dL (females); serum trans-
ferrin, 215-365 mg/dL (males) and 250-380 mg/dL
(females); transferrin saturation, 7-53%; and serum ferri-
tin 10-295 ng/mL (males) and 25-325 ng/mL (females).
Genetic analysis of the HAMP promoter
Blood samples were collected and DNA was extracted
from peripheral blood leucocytes following standard
procedures. A fragment of 951bp that extended from
nucleotide 1013 upstream the ATG translation initiation
codon of HAMP to 9bp downstream of exon 1 was PCR
amplified with the following pair of primers: forward 5’-
GTACTCATCGGACTGTAGATGTTAGC-3’ and
reverse 5’-GTGACAGTCGCTTTTATGGGGCCTGC-3’.
PCR products were purified and both strands were
directly sequenced using the BigDye terminator kit and
run in the 3730 }l DNA analyzer (Applied Biosystems,
Foster City, CA, USA).
G variant genotype",1,0,1,0,0pc,0pc,0pc,0pc>c.-582A > G
variant genotype
The rs10421768 polymorphism located 582 bp upstream
the ATG translation initiation codon was genotyped using
the TaqMan® functionally tested assay c_2604942_10 in a
7300 Real-Time PCR system (Applied Biosystems).
Cell culture
The human hepatoma cell line HepG2 was obtained
from the European Cell Culture Collection (ECACC,
UK) and maintained in Dulbecco’s modified media
(DMEM) with 4500 mg/L glucose supplemented with
10% foetal bovine serum, 2 mM glutamine, 50 units/mL
penicillin, 50 μg/mL streptomycin and 100 μg/mL
neomycin.
Plasmids
Two 951 bp fragments, which included 942bp of the
human HAMP promoter plus 9 bp of 5’UTR of exon 1
were PCR amplified from homozygous c.-582A and c.-




PCR products were double-digested with HindIII and
XhoI restriction enzymes (Promega Corporation, Madi-
son, WA, USA). VarA-Hep/Luc and VarG-Hep/Luc
constructs were generated using T4 DNA ligase (Pro-
mega) by cloning digested products into the same
restriction sites of pGL3-Control vector (Promega). The
nucleotide sequence of the constructs was confirmed by
DNA sequencing.
Plasmids pCMV-USF1 and pCMV-USF2, (kindly pro-
vided by Dr. M. Sawadogo University of Texas, MD
USA and Dr. H K. Bayele University College London
UK), were used for transactivation assays.
Luciferase assays
Approximately 1.4 × 105 HepG2 cells were plated in 12-
well plates 24 h before transfection. Cells were transi-
ently transfected with 1000 ng of DNA using FugeneHD
transfection reagent at an 8:2 ratio according to manu-
facturer’s protocol (Roche Applied Sciences, Indianapo-
lis, USA). For promoter transactivation assays cells were
transiently cotransfected with 350 ng of Hep/Luc con-
structs and 450 ng of pCMV-USF1, pCMV-USF2 or the
combination of these latter two plasmids at a 1:1 ratio.
In all cases, 200 ng of pRL-TK vector (Promega) was
included as an internal control of transfection efficiency.
When necessary, pcDNA3.1 empty vector was used to
equalize the total amount of DNA. pGL3-Control vector
was used in each experiment as an interassay control to
normalize transfection efficiencies. Cells were incubated
with transfection reagents for 48 h at 37°C in full
DMEM media, followed by further 18 h incubation in
fresh full media. Luciferase and Renilla activities were
determined using Dual-Glo®Luciferase Assay System
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(Promega) according to manufacturer’s protocol. Lumi-
niscence was measured in a TRIAD LT luminometer
(Dynex Technologies, Chantilly, VA, USA). All the
experiments were independently performed in triplicate.
Transactivation of the HAMP promoter is expressed
as fold induction of luciferase/renilla luminescence ratio
of Hep/Luc expressing cells over the ratio obtained
from cells transfected with pGL3-Control vector. Data
are presented as mean values ± SEM.
Statistical analysis
Statistical analysis was performed using SPSS analysis
software v.16.0 (SPSS Inc., Chicago, IL, USA). The dif-
ferences found in the values of the biochemical indica-
tors of iron status among the various genotypes at
position c.-582 were tested by the Mann-Whitney and
Kruskal-Wallis tests. The results from Luciferase assays
were compared using one-way ANOVA for repeated
measurements followed by Tukey’s posthoc test. These
analyses were performed using GraphPad Prism v.5.0
(GraphPad Software, San Diego, California). In all cases
a p value less than 0.05 was considered significant.
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